Palisade Bio Commences Dosing in First Ulcerative Colitis Patient Cohort in Ongoing Phase 1a/b Study of PALI-2108
Positive preliminary data from all five single ascending dose (SAD) cohorts and first three completed multiple ascending dose (MAD) cohorts ...
MyChesCo on MSN12h
Johnson & Johnson Reports Positive Study Results for Ulcerative Colitis Treatment
HOUSE, PA — Johnson & Johnson (NYSE: JNJ) announced promising topline data from its Phase 2b ANTHEM-UC clinical trial evaluating icotrokinra (JNJ-2113) as a treatment for moderately to severely active ...
Precision Medicine Online6h
RedHill Biopharma to Launch Phase II Trial of Crohn's Disease Drug in Biomarker-Defined Population
The drug, RHB-204, is a next-generation formulation of a separate candidate from RedHill, RHB-104, which showed positive results in a Phase III trial.